Abstracts tagged "Pediatric rheumatology"

Abstract Number: 0371 • ACR Convergence 2023
Assessing Methotrexate Adherence in JIA Using Electronic Health Record-Linked Pharmacy Dispensing Data
Dori Abel¹, David Anderson¹, Michael Kallan², Levon Utidjian¹, Joyce Chang³, Chen Kenyon¹ and Sabrina Gmuca¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Boston Children's Hospital, Boston, MA
Background/Purpose: The extent to which lack of adherence to prescribed treatment regimens contributes to differential disease outcomes in JIA – and demographic disparities in these…
Abstract Number: 0834 • ACR Convergence 2023
Characterization of the Youngest Cohort with Non-Systemic Juvenile Idiopathic Arthritis: Demographics and Medication Use of Patients ≤2 Years of Age in the Childhood Arthritis and Rheumatology Research Alliance Registry
Christina Gulla¹, Tara Lozy², Daniel Choi³, Ginger Janow⁴ and For The CARRA Registry Investgators⁵, ¹HUMC pediatrics residency, Hackensack, NJ, ²Ccenter for Discovery and Innovation, Hackensack, NJ, ³Hackensack Meridian School of Medicine, Nutley, NJ, ⁴Joseph M. Sanzari Children's Hospital at Hackensack Meridian Health, Glen Rock, NJ, ⁵CARRA, Inc, Washington, DC
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children. Tumor necrosis factor inhibitors (TNFi) have demonstrated efficacy and safety in older…
Abstract Number: 1231 • ACR Convergence 2023
Successful Implementation of a Mental Health Screening Program for Youth with Juvenile Dermatomyositis
Y. Ingrid Goh¹, Kayla Baker¹, Audrey Bell-Peter¹, Vanessa Carbone¹, Brian Feldman¹, Luana Flores Pereira¹, Jayne MacMahon¹, Valerio Maniscalco¹, Jo-Anne Marcuz¹, Greta Mastrangelo², Tanya Slater¹, Kristi Whitney¹ and Andrea Knight¹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²Division of Rheumatology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: High levels of emotional distress have been reported in children with juvenile myositis (JM). Inadequate recognition of mental health concerns by healthcare providers (HCPs)…
Abstract Number: 1251 • ACR Convergence 2023
Neurologic Manifestations of Pediatric Sjogren’s Disease Patients: Case Series from an Academic Children’s Hospital
Maya Faison¹, Catherine Lavallee², Joseph McDonald¹ and Cuoghi Edens¹, ¹University of Chicago Medicine, Chicago, IL, ²Virginia Tech Carilion School of Medicine, Roanoke, VA
Background/Purpose: The prevalence of Sjogren's disease (SD) is becoming increasingly recognized in pediatric rheumatology. Despite fewer sicca symptoms, it has been shown that pediatric SD…
Abstract Number: 1686 • ACR Convergence 2023
Adolescent and Young Adult Rheumatology Patient Reports of Reproductive Health Screening and Counseling in the Clinical Setting
Brittany Huynh¹, Mary Ott¹ and Stacey Tarvin², ¹Indiana University School of Medicine, Indianapolis, IN, ²Riley Hospital for Children at Indiana University Health, Indianapolis, IN
Background/Purpose: Adolescents and young adults (AYAs) with rheumatic disease are at high risk of poor reproductive health outcomes due to disease-related risks and teratogen use.…
Abstract Number: 2050 • ACR Convergence 2023
Variability in Vaccination Practices in Children with Rheumatic Diseases: Results of a Rheumatology Provider Childhood Arthritis and Rheumatology Research Alliance (CARRA)-wide Survey
Randal De Souza¹, Merav Heshin Bekenstein², Beth Rutstein³, Maria Schletzbaum⁴, Nora Singer⁵, Melanie Kohlheim⁶, vincent del gaizo⁷, Kelly Wise⁸, Melica Nikahd⁹, Guy Brock¹⁰, Rebecca Sadun¹¹, Monica Ardura¹, Vidya Sivaraman¹ and For The CARRA Registry Investgators⁷, ¹Nationwide Children's Hospital, Columbus, OH, ²Dana Children's Hospital of Tel Aviv Medical Center, Tel Aviv, Israel, ³Division of Rheumatology at Children's Hospital of Philadelphia, Philadelphia, PA, ⁴St. Louis Children’s Hospital / Washington University in St. Louis, Middleton, WI, ⁵The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH, ⁶Self, Granville, OH, ⁷CARRA, Inc, Washington, DC, ⁸Nationwide Children's Hospital, Hilliard, OH, ⁹Ohio State University, Columbus, OH, ¹⁰Dept. of Biomedical Informatics, Columbus, OH, ¹¹Duke University, Durham, NC
Background/Purpose: Immunocompromised children (ICC), including children with rheumatic diseases receiving immunosuppressive therapies (IST) are at increased risk of morbidity from vaccine-preventable infections. The 2022 American…
Abstract Number: 2476 • ACR Convergence 2023
Defining Cutoffs for Disease Activity States in Systemic Juvenile Idiopathic Arthritis Based on the Systemic Juvenile Arthritis Disease Activity Score
Silvia Rosina¹, Ana Isabel Rebollo Gimenez², Letizia Tarantola¹, Yulia Vyzhga¹, Luca Carlini³, Elisa Patrone⁴, Maria Katsikas⁵, Claudia Saad-Magalhaes⁶, Dalia El-Ghoneimy⁷, Yasser El Miedany⁸, Raju Khubchandani⁹, Priyankar Pal¹⁰, Gabriele Simonini¹¹, Giovanni Filocamo¹², Maurizio Gattinara¹³, Fabrizio De Benedetti¹⁴, Davide Montin¹⁵, Adele Civino¹⁶, Muatasem Alsuweiti¹⁷, Valda Stenevicha¹⁸, Vyacheslav Chasnyk¹⁹, Ekaterina Alexeeva²⁰, Sulaiman Al-Mayouf²¹, Soamarat Vilayuk²², Angela Pistorio²³ and Angelo Ravelli²⁴, ¹IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Autoinfiammatorie, Genova, Italy, ²IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Autoinfiammatorie, Genoa, Italy, ³IRCCS Istituto Giannina Gaslini, UOC Servizio di Sperimentazioni Cliniche Pediatriche, PRINTO, Genoa, Italy, ⁴IRCCS Istituto Giannina Gaslini, UOC Servizio di Sperimentazioni Cliniche Pediatriche, PRINTO, Genova, Italy, ⁵Hospital de Pediatria Juan P Garrahan, Servicio de Inmunologia/Reumatologia, Buenos Aires, Argentina, ⁶Sao Paulo State University, Botucatu, Brazil, ⁷PAIR Unit, Children's Hospital Ain Shams University, Cairo, Egypt, ⁸Ain Shams University, Italian Hospital St Abbassia, Cairo, Egypt, ⁹SRCC Childrens Hospital, Mumbai, India, ¹⁰Institute of Child Health, Pediatric Medicine, Kolkata, India, ¹¹Rheumatology Unit, ERN ReConnet Center, Meyer Children's Hospital IRCCS, Florence Italy. NeuroFARBA Department, University of Florence, Florence, Italy, ¹²Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Pediatric Rheumatology, Milan, Italy, ¹³Istituto Gaetano Pini, Divisione di Reumatologia, Milan, Italy, ¹⁴Bambino Gesu Children's Hospital, Division of Rheumatology, Rome, Italy, ¹⁵Immunology and Rheumatology Unit, Regina Margherita Children Hospital, Turin, Italy, ¹⁶P.O. Vito Fazzi, Uo Pediatria - Sezione Reumatologia e Immunologia Pediatrica, Lecce, Italy, ¹⁷King Hussein Medical Center, Department of Pediatrics, Amman, Jordan, ¹⁸Department of Paediatrics, Riga Stradins University, Children University Hospital, Riga, Latvia, ¹⁹Saint-Petersburg State Pediatric Medical University, Pediatrics, Saint-Petersburg, Russia, ²⁰Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, ²¹King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia, ²²Mahidol University Faculty of Medicine, Ramathibodi Hospital, Bangkok, Thailand, ²³Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Genoa, Italy, ²⁴Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: The systemic Juvenile Arthritis Disease Activity Score (sJADAS) is a composite disease activity (DA) score specifically validated for use in systemic JIA (sJIA), whose…
Abstract Number: 0350 • ACR Convergence 2023
Presentation, Management, and Outcomes of Systemic JIA-Associated Lung Disease: A Single Center Experience
Ana Luiza Altaffer¹, Maria Pereira², Marietta De Guzman² and Andrea Ramirez², ¹Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Houston, TX
Background/Purpose: Interstitial lung disease (ILD) is a rare and severe complication of systemic juvenile idiopathic arthritis (SJIA) that was recognized relatively recently, and its incidence…
Abstract Number: 0372 • ACR Convergence 2023
Efficacy and Safety of Secukinumab in Juvenile Idiopathic Arthritis: Interim Results from the Extension of the JUNIPERA Trial
Hermine Brunner¹, Ivan Foeldvari², Ekaterina Alexeeva³, Nuray Aktay Ayaz⁴, Grant Schulert⁵, Seza Ozen⁶, Artem Popov⁷, Athimalaipet V Ramanan⁸, Christiaan Scott⁹, Betul Sozeri¹⁰, Elena Zholobova¹¹, Sudhanshu Chakraborty¹², Xuan Zhu¹³, Ruvie Martin¹³, Sarah Whelan¹⁴, Sharonjeet Kaur¹⁵, Luminita Pricop¹³, Daniel J Lovell¹⁶, Alberto Martini¹⁷ and Nicolino Ruperto¹⁸, ¹Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ²Hamburger Zentrum fuer Kinder und Jugendrheumatologie, Rheumatology, Hamburg, Germany, ³National Scientific and Practical Center of Children's Health, Rheumatology, Moscow, Russia, ⁴Department of Pediatric Rheumatology, Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Hacettepe University Medical Faculty, Ankara, Turkey, ⁷Ural State Medical University Ekaterinburg, Sverdlovsk, Russia, ⁸Bristol Royal Hospital for Children & Translational Health Sciences, University of Bristol, Bristol, United Kingdom, ⁹Department of Paediatric Rheumatology, Red Cross War Memorial Children’s Hospital, University of Cape Town, Cape Town, South Africa, ¹⁰Division of Pediatric Rheumatology, University of Health Sciences, Ümraniye Training and Research Hospital, Istanbul, Turkey, ¹¹First Moscow State Medical University, n.a. I.M.Sechenov, Moscow, Russia, ¹²IQVIA, Durrham, NC, ¹³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁴Novartis Ireland Ltd, Dublin, Ireland, ¹⁵Novartis Pharma AG, Basel, Switzerland, ¹⁶UC Department of Pediatrics, Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, OH, ¹⁷Università di Genova, Genova, Italy, ¹⁸IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Genova, Italy
Background/Purpose: Secukinumab has demonstrated efficacy and safety in patients with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) categories of juvenile idiopathic arthritis (JIA) for…
Abstract Number: 0918 • ACR Convergence 2023
Network Analysis of Genome Sequences Identifies Important Pathways in the Pathogenesis of Childhood-onset Systemic Lupus Erythematosus
Katie Heitzman¹, Sneha Dass¹, Linda Hiraki², Earl Silverman³, Christiaan Scott⁴, Ana Barrera-Vargas⁵, Zuoming Deng⁶, Mariana Kaplan⁷, Luis Franco⁸ and Laura Lewandowski⁹, ¹Lupus Genetics and Global Health Disparities Unit, Systemic Autoimmunity Branch, NIAMS, Bethesda, MD, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Silverman, Toronto, ON, Canada, ⁴Paediatric Rheumatology, Red Cross War Memorial Children’s Hospital and University of Cape Town, Cape Town, South Africa, ⁵Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁶National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁷Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH); Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, ⁸Functional Immunogenomics Section, Systemic Autoimmunity Branch, NIAMS, NIH, Bethesda, MD, ⁹Lupus Genetics and Global Health Disparities Unit, Systemic Autoimmunity Branch, NIAMS, NIH, Bethesda, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disorder. The pathogenesis of SLE is not fully understood, but high twin/sibling concordance rates suggest…
Abstract Number: 1232 • ACR Convergence 2023
Improvement Across Organ System, Physician and Patient Reported Outcome Measures over a 36-time Period in the Juvenile Systemic Scleroderma Inception Cohort
Ivan Foeldvari¹, Jens Klotsche², Ozgur Kasapcopur³, Amra Adrovic⁴, Kathryn Torok⁵, Brian Feldman⁶, Maria Teresa TErreri⁷, Ana Sakamoto⁸, Jordi Anton⁹, Simone Appenzeller¹⁰, Edoardo Marrani¹¹, Maria Katsikas¹², Maria Jose Santos¹³, FLAVIO SZTAJNBOK¹⁴, Lillemor Berntson¹⁵, Juergen Brunner¹⁶, Sindhu Johnson¹⁷, Mikhail Kostik¹⁸, Kirsten Minden¹⁹, Farzana Nuruzzaman²⁰ and Nicola Helmus²¹, ¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, ⁴Istanbul University - Cerrahpasa, Istanbul, Turkey, ⁵University of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷UNIFESP, São Paulo, Brazil, ⁸Federal University of São Paulo (UNIFESP), São Paulo, Brazil, ⁹Hospital Sant Joan de Déu, Pediatric Rheumatology Department, Universitat de Barcelona, Barcelona, Spain, ¹⁰UNICAMP, Campinas, Brazil, ¹¹University of Florence, Firenze, Italy, ¹²Hospital de Pediatria Juan P Garrahan, Servicio de Inmunologia/Reumatologia, Buenos Aires, Argentina, ¹³Hospital Garcia de Orta, Almada, Lisboa, Portugal, ¹⁴UFRJ/UERJ, São Paulo, Brazil, ¹⁵Dept. of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, ¹⁶Medical University Innsbruck; Department of Pediatrics, Pediatric Rheumatology, Innsbruck, Austria, ¹⁷Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, ¹⁸Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ¹⁹Charité University Medicine and German Rheumatism Research Center Berlin, Berlin, Germany, ²⁰Stony Brook Children's Hospital, Stony Brook, NY, ²¹Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan disease with a prevalence of 3 in 1, 000, 000 children. The Juvenile Systemic Scleroderma Inception cohort…
Abstract Number: 1252 • ACR Convergence 2023
Physician Global Assessment of Disease Activity in Childhood-Onset Systemic Lupus Erythematosus – Does the Approach Matter?
Ekemini Ogbu¹, Hermine Brunner², Jennifer Huggins³, Angela Merritt³, Megan Quilan-Waters³, Catherine Robben³, Chen Chen³, Daniel J Lovell⁴ and Bin Huang³, ¹Cincinnati Children's Hospital Medical Center, University of Cincinnati School of Medicine, Johns Hopkins University, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴UC Department of Pediatrics, Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, OH
Background/Purpose: Physician Global Assessment of Disease Activity (PhGA) are commonly used outcome measures in pediatric rheumatology. For childhood-onset systemic lupus erythematosus (cSLE), the traditional visual…
Abstract Number: 1705 • ACR Convergence 2023
Reduced DNASE1L3 Activity and Increased Anti-NET Protective Antibodies Contributes to Accumulation of Neutrophil Extracellular Traps in Pediatric SLE Patients
Betsy Barnes¹, Lydia Thomas², Jenna Battaglia Battaglia³, Kim Simpfendorfer³, Joyce Hui-Yuen⁴, Vinay Sharma⁵ and Bharati Matta⁶, ¹Northwell Health, Manhasset, NY, ²Northwell Health - Cohen Children's Medical Center, Lake Success, NY, ³Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, ⁴North Shore LIJ Health System, Great Neck, NY, ⁵Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur, India, ⁶The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY and Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur, NY
Background/Purpose: Pediatric systemic lupus erythematosus (pSLE) is a multisystemic chronic autoimmune disease with high renal involvement. In SLE, neutrophil extracellular traps (NETs) are considered a…
Abstract Number: 2052 • ACR Convergence 2023
Risk Factors for Hospitalization for SARS-CoV-2 in Pediatric Patients with Rheumatic Diseases: A Systematic Review and Meta-analysis
Qianzi Zhao¹, Beth Wallace², Lawrence Jung³ and Tova Ronis⁴, ¹Trinity Health Ann Arbor, Ann Arbor, MI, ²Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ³Jung Medical, Cedar Falls, IA, ⁴Children's National Hospital, Chevy Chase, MD
Background/Purpose: Among adults who develop SARS-CoV-2 infection, those with rheumatic diseases (RDs) have similar hospitalization rates compared to those without RDs. Similar comparisons are lacking…
Abstract Number: 2478 • ACR Convergence 2023
Effect of Conventional and Biologic Disease-Modifying Anti-Rheumatic Drugs on the Antibody Response to Four Doses of COVID-19 mRNA Vaccines in Children with Autoimmune and Rheumatic Diseases
Janna Shapiro¹, Florence Choi², Amy Xu³, Trang Duong⁴, Anne-Claude Gingras⁵, Sasha Bernatsky⁶, Susanne (Susa) Benseler⁷ and Rae Yeung⁸, ¹University of Toronto, Toronto, ON, Canada, ²Hong Kong Hospital Authority, Hong Kong, Hong Kong, ³Division of Rheumatology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, ON, Canada, ⁵Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital Sinai Health, Toronto, ON, Canada, ⁶Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Children with rheumatic and autoimmune diseases are often treated with conventional or biologic disease-modifying antirheumatic drugs (cDMARDs and bDMARDs) to control disease. While effective,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].